Roche’s RoActemra Recommended in Final U.K. Guidance on Juvenile Arthritis

Roche Holding AG (ROG)’s RoActemra won the backing of the U.K.’s National Institute for Health and Clinical Excellence in final guidelines for treating patients with systemic juvenile idiopathic arthritis.

The guidelines would allow RoActemra as an option for children age 2 and older whose illness hasn’t adequately responded to other therapies, as long as Basel, Switzerland- based Roche makes the drug available to the state-run medical system at a discount, the institute, known as NICE, said today in an e-mailed statement.

NICE advises the National Health Service on the cost- effectiveness of treatments.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.